About Peptide Dossier
Updated:
Peptide Dossier is an editorial resource published by Gangotri46 Ventures LLC. The Peptide Dossier Editorial Team covers peptides, GLP-1 receptor agonists, and related compounds. Our goal is a useful, plainly written reference for a field that is fast-moving, heavily marketed, and easy to get wrong. We are not a clinic and we do not sell peptides.
What we cover
We publish reference guides on individual peptides (dosing, mechanism, storage, reconstitution, safety), on the FDA-approved GLP-1 medications (semaglutide, tirzepatide, and others), and on the practical and regulatory questions that surround them. Every guide is meant to help a reader understand a topic, not to instruct them to act on it.
How we research
Our sourcing standard is to link scientific claims to their original studies, trial records or product documentation. Human research, animal experiments and practitioner experience answer different questions, and should not be presented as interchangeable evidence. We use AI assistance and are checking the existing library in risk-prioritized batches, starting with calculations, dosing, preparation and storage. That work is ongoing; an Editorial Team byline does not mean every claim has been verified or that a clinician reviewed the page. Our full standards are in our Editorial Policy.
Editorial recommendations
We receive no compensation for referrals or links. Rankings reflect editorial judgment, not a guarantee that a provider or treatment is the right choice for every reader. See our Advertising Disclosure page for the current policy.
What this site is not
Peptide Dossier does not provide medical advice, diagnosis, or treatment, and nothing here is a substitute for a licensed clinician who can review your history, labs, and medications. Please read our Medical Disclaimer before acting on anything you find here.
Corrections
Medical knowledge changes and errors can occur. To report one, email hello@peptidedossier.com with the page, claim and any supporting source. Our correction process is described in the Editorial Policy.
See also: Editorial Policy, Advertising Disclosure, Medical Disclaimer.